Claims for Patent: 5,747,454

Summary for Patent: 5,747,454

Title:	Chromogranin peptides
Abstract:	This invention relates to synthetic chromogranin A peptides, pharmaceutical compositions comprising these peptides, and uses of the peptides for treating hyperparathyroidism, and treating or preventing conditions associated with hyperparathyroidism such as parathyroid hyperplasia-associated renal failure, osteoporosis, and the like.
Inventor(s):	Angeletti; Ruth Hogue (New Rochelle, NY), Russell; John (Bronx, NY)
Assignee:	Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Application Number:	08/491,544
Patent Claims:	1. A synthetic chromogranin A peptide having the amino acid sequence: X-A-Ile-Val-Glu-Val-Ile-B-Asp-C-Leu-B-Lys-Pro-B-Pro-Met -Pro-Val-B-Lys-Glu-A-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, A is Cys or lanthionine; B is Ser or Ala; C is Thr or Ala; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 2. The peptide of claim 1 having the amino acid sequence: X-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 3. The peptide of claim 2, selected from the group consisting of: (a1) Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys -Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (a2) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (a3) Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys -Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (a4) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (b1) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser -Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (b2) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (b3) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser -Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D -Thr (SEQ ID NO:1); (b4) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (c1) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (c2) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (c3) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (c4) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (d1) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (d2) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (d3) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (d4) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e1) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (e2) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (e3) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e4) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f1) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (f2) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (f3) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f4) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g1) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g2) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g3) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g4) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h1) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h2) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h3) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h4) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i1) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i2) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i3) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i4) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j1) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j2) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO: 1); (j3) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j4) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k1) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k2) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro -Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k3) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k4) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro -Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1). 4. The peptide of claim 1 having the amino acid sequence: X-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 5. The peptide of claim 4, selected from the group consisting of: (a1) Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys -Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (a2) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (a3) Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys -Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (a4) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (b1) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala -Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (b2) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (b3) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala -Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D -Thr (SEQ ID NO:1); (b4) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (c1) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (c2) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (c3) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (c4) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (d1) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (d2) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (d3) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (d4) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e1) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (e2) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (e3) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e4) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f1) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (f2) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (f3) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f4) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g1) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g2) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g3) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g4) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h1) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h2) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h3) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h4) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i1) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i2) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i3) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i4) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j1) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j2) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO: 1); (j3) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j4) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k1) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k2) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro -Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k3) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); and (k4) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro -Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1). 6. A peptide composition comprising a pharmaceutically acceptable carrier and a synthetic chromogranin A peptide having the amino acid sequence: X-A-Ile-Val-Glu-Val-Ile-B-Asp-C-Leu-B-Lys-Pro-B-Pro-Met -Pro-Val-B-Lys-Glu-A-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; A is Cys or lanthionine; B is Ser or Ala; C is Thr or Ala; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 7. The peptide composition of claim 6, wherein the peptide has the amino acid sequence: X-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 8. The peptide composition of claim 7, wherein the peptide is selected from the group consisting of: (a1) Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys -Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (a2) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (a3) Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys -Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (a4) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (b1) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser -Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (b2) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (b3) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser -Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D -Thr (SEQ ID NO:1); (b4) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (c1) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (c2) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (c3) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (c4) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (d1) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (d2) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (d3) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (d4) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e1) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (e2) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (e3) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e4) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f1) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (f2) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (f3) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f4) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g1) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g2) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g3) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g4) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h1) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h2) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h3) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h4) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i1) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i2) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i3) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i4) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j1) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j2) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO: 1); (j3) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j4) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k1) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k2) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro -Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k3) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k4) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro -Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1). 9. The peptide composition of claim 1, wherein the peptide has the amino acid sequence: X-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 10. The peptide composition of claim 9, wherein the peptide is selected from the group consisting of: (a1) Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys -Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (a2) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (a3) Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys -Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (a4) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (b1) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala -Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (b2) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (b3) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala -Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D -Thr (SEQ ID NO:1); (b4) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (c1) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (c2) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (c3) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (c4) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (d1) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (d2) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (d3) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (d4) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e1) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (e2) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (e3) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e4) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f1) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (f2) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (f3) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f4) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g1) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g2) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g3) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g4) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h1) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h2) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h3) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h4) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i1) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i2) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i3) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i4) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j1) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j2) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j3) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j4) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k1) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k2) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro -Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k3) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); and (k4) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro -Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1). 11. A method for inhibiting parathyroid hormone secretion in a subject in need of such inhibition comprising administering to the subject a parathyroid hormone secretion inhibiting amount of a synthetic chromogranin A peptide having the amino acid sequence: X-A-Ile-Val-Glu-Val-Ile-B-Asp-C-Leu-B-Lys-Pro-B-Pro-Met -Pro-Val-B-Lys-Glu-A-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; A is Cys or lanthionine; B is Ser or Ala; C is Thr or Ala; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 12. The method of claim 11, wherein the peptide has the amino acid sequence: X-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 13. The method of claim 12, wherein the peptide is selected from the group consisting of: (a1) Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys -Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (a2) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (a3) Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys -Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (a4) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (b1) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser -Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (b2) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (b3) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser -Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D -Thr (SEQ ID NO:1); (b4) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (c1) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (c2) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (c3) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu -Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (c4) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (d1) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (d2) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (d3) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr -Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (d4) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e1) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (e2) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (e3) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser-Asp -Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e4) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f1) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (f2) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (f3) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ser -Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f4) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g1) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g2) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g3) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val-Ser -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g4) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h1) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h2) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h3) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro-Val -Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h4) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i1) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i2) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i3) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met-Pro -Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i4) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j1) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j2) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO: 1); (j3) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro-Met -Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j4) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser -Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k1) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k2) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro -Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k3) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro-Ser-Pro -Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k4) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ser-Asp-Thr-Leu-Ser-Lys-Pro -Ser-Pro-Met-Pro-Val-Ser-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1). 14. The method of claim 11, wherein the peptide has the amino acid sequence: X-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Y (SEQ ID NO:1), wherein: X is X1 or acetyl-X1, wherein X1 is: Lys-, Met-Lys-, Val-Met-Lys-, Glu-Val-Met-Lys-, Thr-Glu-Val-Met-Lys-, Asp-Thr-Glu-Val-Met-Lys-, Gly-Asp-Thr-Glu-Val-Met-Lys-, Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-, or Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-; and Y is -Phe-Glu or -Phe-Glu-D-Thr. 15. The method of claim 14, wherein the peptide has the amino acid selected from the group consisting of: (a1) Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys -Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (a2) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (a3) Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys -Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (a4) acetyl-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (b1) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala -Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (b2) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (b3) Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala -Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D -Thr (SEQ ID NO:1); (b4) acetyl-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (c1) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu (SEQ ID NO:1); (c2) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (c3) Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu -Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe -Glu-D-Thr (SEQ ID NO:1); (c4) acetyl-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (d1) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu (SEQ ID NO:1); (d2) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (d3) Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala -Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys -Phe-Glu-D-Thr (SEQ ID NO:1); (d4) acetyl-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e1) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu (SEQ ID NO:1); (e2) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (e3) Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala-Asp -Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys-Glu -Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (e4) acetyl-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f1) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu (SEQ ID NO:1); (f2) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (f3) Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile-Ala -Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala-Lys -Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (f4) acetyl-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g1) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g2) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (g3) Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val-Ile -Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val-Ala -Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (g4) acetyl-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h1) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h2) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (h3) Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu-Val -Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro-Val -Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (h4) acetyl-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i1) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i2) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (i3) Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val-Glu -Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met-Pro -Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (i4) acetyl-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j1) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (j2) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO: 1); (j3) Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile-Val -Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro-Met -Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (j4) acetyl-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys -Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala -Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); (k1) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k2) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro -Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu (SEQ ID NO:1); (k3) Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys-Cys-Ile -Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro-Ala-Pro -Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1); and (k4) acetyl-Pro-Met-Asn-Lys-Gly-Asp-Thr-Glu-Val-Met-Lys -Cys-Ile-Val-Glu-Val-Ile-Ala-Asp-Ala-Leu-Ala-Lys-Pro -Ala-Pro-Met-Pro-Val-Ala-Lys-Glu-Cys-Phe-Glu-D-Thr (SEQ ID NO:1). 16. The method of claim 11, wherein the subject has hyperparathyroidism. 17. The method of claim 11, wherein the subject has osteoporosis.

Details for Patent 5,747,454

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2013-06-09